Deazapurines useful as inhibitors of Janus kinases

US 20070207995A1
Filed: 09/28/2006
Published: 09/06/2007
Est. Priority Date: 09/30/2005
Status: Active Grant

First Claim

Patent Images

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof wherein R¹is —

(C_1-2aliphatic)_p-R⁴wherein R¹is optionally substituted with 1-3 occurrences of J;

R²is —

(C_1-2aliphatic)_d-R⁵wherein R²is optionally substituted with 1-3 occurrences of J;

R⁴is H, halogen, CN, NH₂, NO₂, CF₃, C_1-3aliphatic, cyclopropyl, NCH₃, OCH₃, —

C(═

O)NH₂, —

C(═

O)CH₃, —

NHC(═

O)CH₃, or OH;

R⁵is H, halogen, CN, NH₂, NO₂, CF₃, C_1-3aliphatic, cyclopropyl, NCH₃, OCH₃, —

C(═

O)NH₂, —

C(═

O)CH₃, —

NHC(═

O)CH₃, or OH;

J is halogen, OCH₃, OH, NO₂, NH₂, SCH₃, NCH₃, CN or unsubstituted C_1-2aliphatic, or two J groups, together with the carbon to which they are attached, form a cyclopropyl ring or C═

O;

p and d are each independently 0 or 1;

Q is a 5-8 membered aromatic monocyclic ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur, or an 8-12 membered aromatic bicyclic ring having 0-6 heteroatoms selected from nitrogen, oxygen, or sulfur;

wherein Q is optionally substituted with 1-10 occurrences of J^Q;

J^Qis halogen, OCF₃, —

(V_m)—

R″

, —

(V_m)—

CN, —

(V_m)—

NO₂or —

(V_m)—

(C_1-4haloaliphatic), or two J^Qgroups, taken together with the atoms to which they are attached, form a 3-8 membered saturated, partially saturated, or unsaturated ring with 0-3 heteroatoms selected from O, N, or S, wherein said ring is optionally substituted with 0-4 occurrences of J^U;

V is a C_1-10aliphatic, wherein up to three methylene units are replaced by G^V, wherein G^Vis selected from —

NH—

, —

NR—

, —

O—

, —

S—

, —

C(O)O—

, —

OC(O)—

, —

C(O)C(O)—

, —

C(O)—

, —

C(O)NH—

, —

C(O)NR—

, —

C(═

N—

CN), —

NHC(O)—

, —

NRC(O)—

, —

NHC(O)O—

, —

NRC(O)O—

, —

S(O)₂NH—

, —

S(O)₂NR—

, —

NHS(O)₂—

, —

NRS(O)₂—

, —

NHC(O)NH—

, —

NRC(O)NH—

, —

NHC(O)NR—

, —

NRC(O)NR—

, —

OC(O)NH—

, —

OC(O)NR—

, —

NHS(O)₂NH—

, —

NRS(O)₂NH—

, —

NHS(O)₂NR—

, —

NRS(O)₂NR—

, —

S(O)—

, or —

S(O)₂—

; and

wherein V is optionally substituted with 1-6 occurrences of J^V;

R″

is H or an optionally substituted group selected from C_1-6aliphatic, C_3-10cycloaliphatic, C_6-10aryl, 5-10 membered heteroaryl, or 5-10 membered heterocyclyl;

or two R″

groups, or an R″

group and an R group, on the same substituent or different substituents, together with the atom(s) to which they are attached, form an optionally substituted 3-8 membered heterocyclyl;

wherein each optionally substituted R″

group is independently and optionally substituted with 1-6 occurrences of J^R;

R is an optionally substituted group selected from C_1-6aliphatic, C_3-10cycloaliphatic, C_6-10aryl, 5-10 membered heteroaryl, or 5-10 membered heterocyclyl;

or two R groups, on the same substituent or different substituents, together with the atom(s) to which each R group is bound, form an optionally substituted 3-8 membered heterocyclyl;

wherein each R group is independently and optionally substituted with 1-4 occurrences of J^X;

each J^V, J^U, J^X, and J^Rare each independently selected from halogen, L, -(L_n)-R′

, -(L_n)-N(R′

)₂, -(L_n)-SR′

, -(L_n)-OR′

, -(L_n)-(C_3-10cycloaliphatic), -(L_n)-(C_6-10aryl), -(L_n)-(5-10 membered heteroaryl), -(L_n)-(5-10 membered heterocyclyl), oxo, C_1-4haloalkoxy, C_1-4haloalkyl, -(L_n)-NO₂, -(L_n)-CN, -(L_n)-OH, -(L_n)-CF₃, —

C(O)OR′

, —

C(O)OH, —

C(O)R′

, —

C(O)H, —

OC(O)R′

, or —

NC(O)R′

;

or any two J^V, J^U, J^X, or J^Rgroups, on the same substituent or different substituents, together with the atom(s) to which each J^V, J^U, J^X, and J^Rgroup is bound, form a 5-7 membered saturated, unsaturated, or partially saturated ring;

R′

is H or C_1-6aliphatic;

or two R′

groups, or an R′

group and an R group, together with the atom to which they are attached, optionally form a 3-6 membered cycloaliphatic or heterocyclyl, wherein said aliphatic, cycloaliphatic or heterocyclyl is optionally substituted with R*, —

OR*, —

SR*, —

NO₂, —

CF₃, —

CN, —

C(O)OR*, —

C(O)R*, OC(O)R*, or NHC(O)R*, wherein R* is H or an unsubstituted C_1-6aliphatic;

L is a C_1-6aliphatic wherein up to three methylene units are replaced by —

NH—

, —

NR⁶—

, —

O—

, —

S—

, —

C(O)O—

, —

OC(O)—

, —

C(O)C(O)—

, —

C(O)—

, —

C(O)NH—

, —

C(O)NR⁶—

, —

C(═

N—

CN), —

NHC(O)—

, —

NR⁶C(O)—

, —

NHC(O)O—

, —

NR⁶C(O)O—

, —

S(O)₂NH—

, —

S(O)₂NR⁶—

, —

NHS(O)₂—

, —

NR⁶S(O)₂—

, —

NHC(O)NH—

, —

NR⁶C(O)NH—

, —

NHC(O)NR⁶—

, —

NR⁶C(O)NR⁶, —

OC(O)NH—

, —

OC(O)NR⁶—

, —

NHS(O)₂NH—

, —

NR⁶S(O)₂NH—

, —

NHS(O)₂NR⁶—

, —

NR⁶S(O)₂NR⁶—

, —

S(O)—

, or —

S(O)₂—

;

R⁶is selected from C_1-6aliphatic, C_3-10cycloaliphatic, C_6-10aryl, 5-10 membered heteroaryl, or 5-10 membered heterocyclyl;

or two R⁶groups, on the same substituent or different substituents, together with the atom(s) to which each R⁶group is bound, form a 3-8 membered heterocyclyl;

each of m and n is, independently, 0 or 1;

provided that when R²is C₁, NH₂, or NCH₃, then Q is not optionally substituted phenyl; and

when R¹and R²are H, then Q is not

View all claims

3 Assignments

Timeline View

Assignment View

0 Petitions

Accused Products

Abstract

The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

48 Citations

View as Search Results

37 Claims

1. A compound having the formula:
- or a pharmaceutically acceptable salt thereof wherein R¹is —
  
  (C_1-2aliphatic)_p-R⁴wherein R¹is optionally substituted with 1-3 occurrences of J;
  
  R²is —
  
  (C_1-2aliphatic)_d-R⁵wherein R²is optionally substituted with 1-3 occurrences of J;
  
  R⁴is H, halogen, CN, NH₂, NO₂, CF₃, C_1-3aliphatic, cyclopropyl, NCH₃, OCH₃, —
  
  C(═
  
  O)NH₂, —
  
  C(═
  
  O)CH₃, —
  
  NHC(═
  
  O)CH₃, or OH;
  
  R⁵is H, halogen, CN, NH₂, NO₂, CF₃, C_1-3aliphatic, cyclopropyl, NCH₃, OCH₃, —
  
  C(═
  
  O)NH₂, —
  
  C(═
  
  O)CH₃, —
  
  NHC(═
  
  O)CH₃, or OH;
  
  J is halogen, OCH₃, OH, NO₂, NH₂, SCH₃, NCH₃, CN or unsubstituted C_1-2aliphatic, or two J groups, together with the carbon to which they are attached, form a cyclopropyl ring or C═
  
  O;
  
  p and d are each independently 0 or 1;
  
  Q is a 5-8 membered aromatic monocyclic ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur, or an 8-12 membered aromatic bicyclic ring having 0-6 heteroatoms selected from nitrogen, oxygen, or sulfur;
  
  wherein Q is optionally substituted with 1-10 occurrences of J^Q;
  
  J^Qis halogen, OCF₃, —
  
  (V_m)—
  
  R″
  
  , —
  
  (V_m)—
  
  CN, —
  
  (V_m)—
  
  NO₂or —
  
  (V_m)—
  
  (C_1-4haloaliphatic), or two J^Qgroups, taken together with the atoms to which they are attached, form a 3-8 membered saturated, partially saturated, or unsaturated ring with 0-3 heteroatoms selected from O, N, or S, wherein said ring is optionally substituted with 0-4 occurrences of J^U;
  
  V is a C_1-10aliphatic, wherein up to three methylene units are replaced by G^V, wherein G^Vis selected from —
  
  NH—
  
  , —
  
  NR—
  
  , —
  
  O—
  
  , —
  
  S—
  
  , —
  
  C(O)O—
  
  , —
  
  OC(O)—
  
  , —
  
  C(O)C(O)—
  
  , —
  
  C(O)—
  
  , —
  
  C(O)NH—
  
  , —
  
  C(O)NR—
  
  , —
  
  C(═
  
  N—
  
  CN), —
  
  NHC(O)—
  
  , —
  
  NRC(O)—
  
  , —
  
  NHC(O)O—
  
  , —
  
  NRC(O)O—
  
  , —
  
  S(O)₂NH—
  
  , —
  
  S(O)₂NR—
  
  , —
  
  NHS(O)₂—
  
  , —
  
  NRS(O)₂—
  
  , —
  
  NHC(O)NH—
  
  , —
  
  NRC(O)NH—
  
  , —
  
  NHC(O)NR—
  
  , —
  
  NRC(O)NR—
  
  , —
  
  OC(O)NH—
  
  , —
  
  OC(O)NR—
  
  , —
  
  NHS(O)₂NH—
  
  , —
  
  NRS(O)₂NH—
  
  , —
  
  NHS(O)₂NR—
  
  , —
  
  NRS(O)₂NR—
  
  , —
  
  S(O)—
  
  , or —
  
  S(O)₂—
  
  ; and
  
  wherein V is optionally substituted with 1-6 occurrences of J^V;
  
  R″
  
  is H or an optionally substituted group selected from C_1-6aliphatic, C_3-10cycloaliphatic, C_6-10aryl, 5-10 membered heteroaryl, or 5-10 membered heterocyclyl;
  
  or two R″
  
  groups, or an R″
  
  group and an R group, on the same substituent or different substituents, together with the atom(s) to which they are attached, form an optionally substituted 3-8 membered heterocyclyl;
  
  wherein each optionally substituted R″
  
  group is independently and optionally substituted with 1-6 occurrences of J^R;
  
  R is an optionally substituted group selected from C_1-6aliphatic, C_3-10cycloaliphatic, C_6-10aryl, 5-10 membered heteroaryl, or 5-10 membered heterocyclyl;
  
  or two R groups, on the same substituent or different substituents, together with the atom(s) to which each R group is bound, form an optionally substituted 3-8 membered heterocyclyl;
  
  wherein each R group is independently and optionally substituted with 1-4 occurrences of J^X;
  
  each J^V, J^U, J^X, and J^Rare each independently selected from halogen, L, -(L_n)-R′
  
  , -(L_n)-N(R′
  
  )₂, -(L_n)-SR′
  
  , -(L_n)-OR′
  
  , -(L_n)-(C_3-10cycloaliphatic), -(L_n)-(C_6-10aryl), -(L_n)-(5-10 membered heteroaryl), -(L_n)-(5-10 membered heterocyclyl), oxo, C_1-4haloalkoxy, C_1-4haloalkyl, -(L_n)-NO₂, -(L_n)-CN, -(L_n)-OH, -(L_n)-CF₃, —
  
  C(O)OR′
  
  , —
  
  C(O)OH, —
  
  C(O)R′
  
  , —
  
  C(O)H, —
  
  OC(O)R′
  
  , or —
  
  NC(O)R′
  
  ;
  
  or any two J^V, J^U, J^X, or J^Rgroups, on the same substituent or different substituents, together with the atom(s) to which each J^V, J^U, J^X, and J^Rgroup is bound, form a 5-7 membered saturated, unsaturated, or partially saturated ring;
  
  R′
  
  is H or C_1-6aliphatic;
  
  or two R′
  
  groups, or an R′
  
  group and an R group, together with the atom to which they are attached, optionally form a 3-6 membered cycloaliphatic or heterocyclyl, wherein said aliphatic, cycloaliphatic or heterocyclyl is optionally substituted with R*, —
  
  OR*, —
  
  SR*, —
  
  NO₂, —
  
  CF₃, —
  
  CN, —
  
  C(O)OR*, —
  
  C(O)R*, OC(O)R*, or NHC(O)R*, wherein R* is H or an unsubstituted C_1-6aliphatic;
  
  L is a C_1-6aliphatic wherein up to three methylene units are replaced by —
  
  NH—
  
  , —
  
  NR⁶—
  
  , —
  
  O—
  
  , —
  
  S—
  
  , —
  
  C(O)O—
  
  , —
  
  OC(O)—
  
  , —
  
  C(O)C(O)—
  
  , —
  
  C(O)—
  
  , —
  
  C(O)NH—
  
  , —
  
  C(O)NR⁶—
  
  , —
  
  C(═
  
  N—
  
  CN), —
  
  NHC(O)—
  
  , —
  
  NR⁶C(O)—
  
  , —
  
  NHC(O)O—
  
  , —
  
  NR⁶C(O)O—
  
  , —
  
  S(O)₂NH—
  
  , —
  
  S(O)₂NR⁶—
  
  , —
  
  NHS(O)₂—
  
  , —
  
  NR⁶S(O)₂—
  
  , —
  
  NHC(O)NH—
  
  , —
  
  NR⁶C(O)NH—
  
  , —
  
  NHC(O)NR⁶—
  
  , —
  
  NR⁶C(O)NR⁶, —
  
  OC(O)NH—
  
  , —
  
  OC(O)NR⁶—
  
  , —
  
  NHS(O)₂NH—
  
  , —
  
  NR⁶S(O)₂NH—
  
  , —
  
  NHS(O)₂NR⁶—
  
  , —
  
  NR⁶S(O)₂NR⁶—
  
  , —
  
  S(O)—
  
  , or —
  
  S(O)₂—
  
  ;
  
  R⁶is selected from C_1-6aliphatic, C_3-10cycloaliphatic, C_6-10aryl, 5-10 membered heteroaryl, or 5-10 membered heterocyclyl;
  
  or two R⁶groups, on the same substituent or different substituents, together with the atom(s) to which each R⁶group is bound, form a 3-8 membered heterocyclyl;
  
  each of m and n is, independently, 0 or 1;
  
  provided that when R²is C₁, NH₂, or NCH₃, then Q is not optionally substituted phenyl; and
  
  when R¹and R²are H, then Q is not
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)
- - 2. The compound according to claim 1, wherein Q is a 5-10 membered heteroaryl ring optionally substituted with 1-5 J^Qgroups.
  - 3. The compound according to claim 2 having the formula:
4. The compound according to claim 3, wherein J^Qis wherein each R⁸is, independently, optionally substituted with up to two occurrences of J^V;
- and r is 0 or 1.
5. The compound according to claim 4, wherein J^Qis wherein R⁸is optionally substituted with up to two occurrences of J^V.
6. The compound according to claim 5, wherein R⁸is selected from
7. The compound according to claim 3, wherein r is 0 and R¹, R⁸, and the intervening carbon together are
8. The compound according to claim 4, wherein each of Z¹and Z²is N.
9. The compound according to claim 4, wherein R″
- is CF₃, CH₂CF₃or CH₂CH₂CF₃.
10. The compound according to claim 2, wherein Q is a 5-6 membered heteroaryl ring optionally substituted with 1-3 J^Qgroups.
11. The compound according to claim 10, wherein Q is a 6-membered heteroaryl ring selected from pyridyl, pyrimidyl, pyrazinyl, triazinyl or pyridazinyl optionally substituted with 1-3 J^Qgroups.
12. The compound according to claim 11 having the formula:
- wherein Z²is CH or N;
  
  Z³is C-J^Q3or N;
  
  J^Q1is —
  
  N(R′
  
  )R″
  
  , —
  
  CH₂N(R′
  
  )R″
  
  , —
  
  NR′
  
  C(O)R″
  
  , —
  
  NR′
  
  C(O)R⁹R″
  
  , —
  
  NR′
  
  C(O)OR″
  
  , —
  
  NR′
  
  C(O)OR⁹R″
  
  , —
  
  NR′
  
  C(R′
  
  )(R⁸)R″
  
  , —
  
  NR′
  
  C(R′
  
  )(R⁸)C(O)OR″
  
  , —
  
  N(R′
  
  )R⁹R″
  
  , —
  
  N(R′
  
  )R⁹R″
  
  , —
  
  N(R′
  
  )R⁹N(R′
  
  )R″
  
  , —
  
  N(R′
  
  )R⁹OR″
  
  , —
  
  NR′
  
  C(R′
  
  )(R⁸)R″
  
  , —
  
  NR′
  
  CH₂C(O)N(R′
  
  )R″
  
  or —
  
  NR′
  
  CR′
  
  (R⁸)C(O)N(R′
  
  )R″
  
  ;
  
  J^Q2is hydrogen, —
  
  C(O)OH, —
  
  C(O)OR″
  
  , —
  
  C(O)OR⁹R″
  
  , —
  
  C(O)R″
  
  , —
  
  C(O)R⁹R″
  
  , —
  
  C(O)NHR″
  
  , —
  
  C(O)N(R)R″
  
  , —
  
  C(O)NHR⁹OR″
  
  , —
  
  C(O)NHR⁹R″
  
  , —
  
  C(O)N(R)R⁹R″
  
  , —
  
  OH, —
  
  OR″
  
  , —
  
  CN, or —
  
  R″
  
  ;
  
  wherein R⁸is H, C_1-6alkyl, CF₃, CH₂CF₃, CH₂CN, or CH₂OR″
  
  ;
  
  or R⁸and R′
  
  , taken together with the atom(s) to which they are attached, form a 3-8 membered ring having 0-3 heteroatoms selected from O, N, or S, wherein R⁸or said ring is optionally substituted with 0-4 occurrences of J^V; and
  
  R⁹is C_1-6aliphatic;
  
  or R⁹and R or R′
  
  , taken together with the atom(s) to which they are attached, form a 3-8 membered ring having 0-3 heteroatoms selected from O, N, or S, wherein R⁹or said ring is optionally substituted with 0-4 occurrences of J^V; and
  
  J^Q3is hydrogen, halo, or NO₂.
13. The compound according to claim 12, wherein Z²is CH.
14. The compound according to claim 12, wherein Z²is N.
15. The compound according to claim 12, wherein Z³is C-J^Q3.
16. The compound according to claim 15, wherein J^Q3is F.
17. The compound according to claim 15, wherein J^Q3is H.
18. The compound according to claim 12, wherein Z³is N.
19. The compound according to claim 18, wherein Z²is N.
20. The compound according to claim 12, wherein J^Q2is hydrogen.
21. The compound according to according to claim 12, wherein J^Q2is —
- C(O)OH, —
  
  C(O)OR″
  
  , —
  
  C(O)R″
  
  , —
  
  C(O)NHR″
  
  , —
  
  C(O)N(R)R″
  
  , —
  
  C(O)N(R)R⁹R″
  
  , —
  
  CN, or —
  
  R″
  
  , wherein J^Q2is optionally substituted with up to two occurrences of J^V.
22. The compound according to claim 12, wherein J^Q1is wherein R⁸is optionally substituted with up to two occurrences of J^V.
23. The compound according to claim 22, wherein J^Q1is wherein R⁸is optionally substituted with up to two occurrences of J^V.
24. The compound according to claim 23, wherein R⁸is selected from
25. The compound according to claim 22, wherein J^Q1is wherein ring A is optionally substituted with up to four occurrences of J^V.
26. The compound according to claim 25, wherein Ring A is selected from wherein J^V′
- is H or J^V.
27. The compound according to claim 22, wherein J^Q1is
28. The compound according to claim 27, wherein R′
- , R⁸, and the intervening carbon together are
29. The compound according to according to claim 22, wherein R″
- is CF₃, CH₂CF₃, or CH₂CH₂CF₃.
30. The compound according to claim 1, wherein said compound is selected from:
31. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
32. The composition according to claim 31, said composition additionally comprising a therapeutic agent selected from a chemotherapeutic or anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating destructive bone disorders, an agent for treating liver disease, an anti-viral agent, an agent for treating blood disorders, an agent for treating diabetes, or an agent for treating immunodeficiency disorders.
33. A method of inhibiting JAK kinase activity in a biological sample, comprising contacting said biological sample with a compound according to claim 1.
34. A method of treating or lessening the severity of a disease of condition selected from allergic or type I hypersensitivity reactions, asthma, diabetes, Alzheimer'"'"'s disease, Huntington'"'"'s disease, Parkinson'"'"'s disease, AIDS-associated dementia, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, cardiomyocyte hypertrophy, reperfusion/ischemia, stroke, baldness, transplant rejection, graft versus host disease, rheumatoid arthritis, a solid malignancy, a hematologic malignancy, a leukemia, a lymphoma and a myeloproliferative disorder, said method comprising the step of administering to said patient a compound according to claim 1.
35. The method according to claim 34, wherein said disease or disorder is asthma.
36. The method according to claim 34, wherein said disease or disorder is transplant rejection.
37. The method according to claim 34, wherein said disease is a myeloproliferative disorder selected from polycythemia vera, essential thrombocythemia, chronic idiopathic myelofibrosis, myeloid metaplasia with myelofibrosis, chronic myeloid leukemia, chronic myelomonocytic leukemia, chronic eosinophilic leukemia, hypereosinophilic syndrome, or systematic mast cell disease.

Specification

Resources

Litigation Campaign Assessment

Current Assignee
Vertex Pharmaceuticals Incorporated
Original Assignee
Vertex Pharmaceuticals Incorporated
Inventors
Farmer, Luc, Wang, Tiansheng, Pierce, Albert, Aronov, Alexander, Wang, Jian, Lauffer, David, Duffy, John, Wannamaker, Marion, Martinez-Botella, Gabriel, Bethiel, Randy, Salituro, Francesco

Granted Patent

US 8,580,802 B2
Time in Patent Office

Days
Field of Search
US Class Current

514/210.210
CPC Class Codes

A61P 11/06   Antiasthmatics

A61P 17/14   for baldness or alopecia

A61P 19/08   for bone diseases, e.g. rac...

A61P 21/00   Drugs for disorders of the ...

A61P 25/00   Drugs for disorders of the ...

A61P 25/14   for treating abnormal movem...

A61P 25/16   Anti-Parkinson drugs

A61P 25/18   Antipsychotics, i.e. neurol...

A61P 25/28   for treating neurodegenerat...

A61P 29/00   Non-central analgesic, anti...

A61P 3/10   for hyperglycaemia, e.g. an...

A61P 35/00   Antineoplastic agents

A61P 35/02   specific for leukemia

A61P 37/00   Drugs for immunological or ...

A61P 37/06   Immunosuppressants, e.g. dr...

A61P 37/08   Antiallergic agents antiast...

A61P 43/00   Drugs for specific purposes...

A61P 7/00   Drugs for disorders of the ...

A61P 9/00   Drugs for disorders of the ...

A61P 9/10   for treating ischaemic or a...

C07D 487/04 : Ortho-condensed systems

View All

Deazapurines useful as inhibitors of Janus kinases

First Claim

3 Assignments

0 Petitions

Accused Products

Abstract

48 Citations

37 Claims

Specification

Solutions

Use Cases

Quick Links

Deazapurines useful as inhibitors of Janus kinases

First Claim

3 Assignments

Subscription Required

Subscription Required

0 Petitions

Subscription Required

Accused Products

Subscription Required

Abstract

48 Citations

37 Claims

Specification

Subscription Required

Solutions

Use Cases

Quick Links